Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Insights Imaging ; 11(1): 12, 2020 Feb 05.
Article in English | MEDLINE | ID: mdl-32025985

ABSTRACT

We summarise here the information to be provided to women and referring physicians about percutaneous breast biopsy and lesion localisation under imaging guidance. After explaining why a preoperative diagnosis with a percutaneous biopsy is preferred to surgical biopsy, we illustrate the criteria used by radiologists for choosing the most appropriate combination of device type for sampling and imaging technique for guidance. Then, we describe the commonly used devices, from fine-needle sampling to tissue biopsy with larger needles, namely core needle biopsy and vacuum-assisted biopsy, and how mammography, digital breast tomosynthesis, ultrasound, or magnetic resonance imaging work for targeting the lesion for sampling or localisation. The differences among the techniques available for localisation (carbon marking, metallic wire, radiotracer injection, radioactive seed, and magnetic seed localisation) are illustrated. Type and rate of possible complications are described and the issue of concomitant antiplatelet or anticoagulant therapy is also addressed. The importance of pathological-radiological correlation is highlighted: when evaluating the results of any needle sampling, the radiologist must check the concordance between the cytology/pathology report of the sample and the radiological appearance of the biopsied lesion. We recommend that special attention is paid to a proper and tactful approach when communicating to the woman the need for tissue sampling as well as the possibility of cancer diagnosis, repeat tissue sampling, and or even surgery when tissue sampling shows a lesion with uncertain malignant potential (also referred to as "high-risk" or B3 lesions). Finally, seven frequently asked questions are answered.

2.
Neuropsychopharmacol Hung ; 18(2): 115-8, 2016 06.
Article in Hungarian | MEDLINE | ID: mdl-27390208

ABSTRACT

Marchiafava-Bignami disease (MBD) is caused by damage of the corpus callosum. There are acute, subacute and chronic forms, it occurs most frequently among alcoholic patients. A variety of neurological symptoms, epileptic seizures, and coma may be associated with the disease, but the chronic form may start with acute confusion and dementia, interhemispherial disconnection syndrome or with slow progressive changes in behavior. In 2001, only 250 cases were reported, of which 200 died, 30 cases contributed to severe dementia or bed rest, and favorable outcome occured in only 20 cases. The MBD diagnosis of our patient was based on the anamnesis and cranial MRI and the treatment consisted of administration of B vitamin complex, folic acid, memantine, piracetam and haloperidol. Reviewing the international literature currently recommended therapeutic options are thiamin and folic acid. According to some authors the immediate administration of thiamine affects the outcome of the disease, and there are case reports of beneficial effects of amantadine and steroids.


Subject(s)
Marchiafava-Bignami Disease , Alcoholism , Corpus Callosum , Humans , Magnetic Resonance Imaging , Marchiafava-Bignami Disease/complications , Marchiafava-Bignami Disease/diagnosis , Marchiafava-Bignami Disease/therapy , Thiamine/therapeutic use , Vitamin B Complex/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...